Abstract
The role of elevated triglyceride (TG) levels in the pathogenesis of atherosclerosis is controversial. Some studies suggest that TG might play a direct role in the development of vascular disease. Elevated TG levels are also associated with other vascular risk factors and may therefore represent an indirect marker of a high risk state. Another issue is that laboratory measurements of TG levels frequently show a substantial variability. Accumulating epidemiological data show that there is an independent association of TG levels with vascular risk. Some interventional studies also suggested that lowering TG levels might prevent vascular events. It appears that TG might be more important as therapeutic targets against a background of optimal low density lipoprotein cholesterol (LDL-C) levels. In this context, statins that are more effective in reducing TG levels, fibrates that can safely be combined with statins or fixed fibrate and statin combinations, as well as new, better tolerated nicotinic acid formulations might prove to be particularly beneficial.
Keywords: Triglyceride, statins, fibrates, nicotinic acid, cardiovascular disease, vascular risk
Current Drug Targets
Title: Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies
Volume: 10 Issue: 4
Author(s): Konstantinos Tziomalos, Vasilios G. Athyros, Asterios Karagiannis, Genovefa D. Kolovou and Dimitri P. Mikhailidis
Affiliation:
Keywords: Triglyceride, statins, fibrates, nicotinic acid, cardiovascular disease, vascular risk
Abstract: The role of elevated triglyceride (TG) levels in the pathogenesis of atherosclerosis is controversial. Some studies suggest that TG might play a direct role in the development of vascular disease. Elevated TG levels are also associated with other vascular risk factors and may therefore represent an indirect marker of a high risk state. Another issue is that laboratory measurements of TG levels frequently show a substantial variability. Accumulating epidemiological data show that there is an independent association of TG levels with vascular risk. Some interventional studies also suggested that lowering TG levels might prevent vascular events. It appears that TG might be more important as therapeutic targets against a background of optimal low density lipoprotein cholesterol (LDL-C) levels. In this context, statins that are more effective in reducing TG levels, fibrates that can safely be combined with statins or fixed fibrate and statin combinations, as well as new, better tolerated nicotinic acid formulations might prove to be particularly beneficial.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Athyros G. Vasilios, Karagiannis Asterios, Kolovou D. Genovefa and Mikhailidis P. Dimitri, Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies, Current Drug Targets 2009; 10 (4) . https://dx.doi.org/10.2174/138945009787846425
DOI https://dx.doi.org/10.2174/138945009787846425 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy Homocysteine and Cerebral Stroke in Developing Countries
Current Medicinal Chemistry Gene-environment Interactions in Late Life: Linking Psychosocial Stress with Brain Aging
Current Neuropharmacology Therapeutic Apheresis in Metabolic Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Diabetic Vasculopathy and the Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1)
Current Diabetes Reviews GSK-3 Inhibitors: A New Class of Drugs for Alzheimer’s Disease Treatment
Current Drug Targets Does Caffeine Affect Cardiovascular Responses?
Vascular Disease Prevention (Discontinued) Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design The Role of Matrix Metalloproteinases in Diabetes Mellitus
Current Topics in Medicinal Chemistry Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines
Current Cardiology Reviews Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases
Current Neurovascular Research Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Will Pharmacogenetics Predict Response to Therapies in Rheumatoid Arthritis?
Current Pharmacogenomics Nitric Oxide Donors as Potential Drugs for the Treatment of Vascular Diseases Due to Endothelium Dysfunction
Current Pharmaceutical Design Resveratrol and Cancer: Chemoprevention, Apoptosis, and Chemoimmunosensitizing Activities
Current Medicinal Chemistry - Anti-Cancer Agents Editorial [Hot topic: Vitamin D Deficiency in Cardiovascular and Renal Disease: New Light Shed on an Old Enemy (Guest Editor: Martin H. de Borst)]
Current Drug Targets Role of Heme Oxygenase-1 in Vascular Disease
Current Pharmaceutical Design Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Cardiovascular Effects of Phosphodiesterase 5 Inhibitors
Current Pharmaceutical Design The Neutrophil: An Underappreciated But Key Player in SLE Pathogenesis
Current Immunology Reviews (Discontinued)